These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 35798841)

  • 1. Synchronous intracellular delivery of EGFR-targeted antibody-drug conjugates by p38-mediated non-canonical endocytosis.
    Takahashi JI; Nakamura S; Onuma I; Zhou Y; Yokoyama S; Sakurai H
    Sci Rep; 2022 Jul; 12(1):11561. PubMed ID: 35798841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and Characterization of Cetuximab-Docetaxel and Panitumumab-Docetaxel Antibody-Drug Conjugates for EGFR-Overexpressing Cancer Therapy.
    Glatt DM; Beckford Vera DR; Prabhu SS; Mumper RJ; Luft JC; Benhabbour SR; Parrott MC
    Mol Pharm; 2018 Nov; 15(11):5089-5102. PubMed ID: 30226780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AGCM-22, a novel cetuximab-based EGFR-targeting antibody-drug-conjugate with highly selective anti-glioblastoma efficacy.
    Li D; Sun X; Li Y; Shang C; Dong Y; Zhao R; Zhang H; Wang Z; Fan S; Ma C; Li X
    Bioorg Med Chem; 2024 Mar; 102():117657. PubMed ID: 38428068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancement of tumor uptake and therapeutic efficacy of EGFR-targeted antibody cetuximab and antibody-drug conjugates by cholesterol sequestration.
    Chen Y; Liu G; Guo L; Wang H; Fu Y; Luo Y
    Int J Cancer; 2015 Jan; 136(1):182-94. PubMed ID: 24798787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EGFR targeting for cancer therapy: Pharmacology and immunoconjugates with drugs and nanoparticles.
    Santos EDS; Nogueira KAB; Fernandes LCC; Martins JRP; Reis AVF; Neto JBV; Júnior IJDS; Pessoa C; Petrilli R; Eloy JO
    Int J Pharm; 2021 Jan; 592():120082. PubMed ID: 33188892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ligand-activated epidermal growth factor receptor (EGFR) signaling governs endocytic trafficking of unliganded receptor monomers by non-canonical phosphorylation.
    Tanaka T; Zhou Y; Ozawa T; Okizono R; Banba A; Yamamura T; Oga E; Muraguchi A; Sakurai H
    J Biol Chem; 2018 Feb; 293(7):2288-2301. PubMed ID: 29255092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Temozolomide Induces Endocytosis of EGFRvIII via p38-Mediated Non-canonical Phosphorylation in Glioblastoma Cells.
    Haryuni RD; Tanaka T; Takahashi JI; Onuma I; Zhou Y; Yokoyama S; Sakurai H
    Biol Pharm Bull; 2021; 44(11):1681-1687. PubMed ID: 34719645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EGFR Targeted Cetuximab-Valine-Citrulline (vc)-Doxorubicin Immunoconjugates- Loaded Bovine Serum Albumin (BSA) Nanoparticles for Colorectal Tumor Therapy.
    Ye Z; Zhang Y; Liu Y; Liu Y; Tu J; Shen Y
    Int J Nanomedicine; 2021; 16():2443-2459. PubMed ID: 33814909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
    Harding J; Burtness B
    Drugs Today (Barc); 2005 Feb; 41(2):107-27. PubMed ID: 15821783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting epidermal growth factor receptor in solid tumors: critical evaluation of the biological importance of therapeutic monoclonal antibodies.
    Gialeli Ch; Kletsas D; Mavroudis D; Kalofonos HP; Tzanakakis GN; Karamanos NK
    Curr Med Chem; 2009; 16(29):3797-804. PubMed ID: 19747140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cetuximab-conjugated iron oxide nanoparticles for cancer imaging and therapy.
    Tseng SH; Chou MY; Chu IM
    Int J Nanomedicine; 2015; 10():3663-85. PubMed ID: 26056447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanoconjugation modulates the trafficking and mechanism of antibody induced receptor endocytosis.
    Bhattacharyya S; Bhattacharya R; Curley S; McNiven MA; Mukherjee P
    Proc Natl Acad Sci U S A; 2010 Aug; 107(33):14541-6. PubMed ID: 20679244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Chimeric Cetuximab-Functionalized Corona as a Potent Delivery System for Microtubule-Destabilizing Nanocomplexes to Hepatocellular Carcinoma Cells: A Focus on EGFR and Tubulin Intracellular Dynamics.
    Poojari R; Kini S; Srivastava R; Panda D
    Mol Pharm; 2015 Nov; 12(11):3908-23. PubMed ID: 26426829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ASCT2 (SLC1A5) is an EGFR-associated protein that can be co-targeted by cetuximab to sensitize cancer cells to ROS-induced apoptosis.
    Lu H; Li X; Lu Y; Qiu S; Fan Z
    Cancer Lett; 2016 Oct; 381(1):23-30. PubMed ID: 27450723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members.
    Wheeler DL; Huang S; Kruser TJ; Nechrebecki MM; Armstrong EA; Benavente S; Gondi V; Hsu KT; Harari PM
    Oncogene; 2008 Jun; 27(28):3944-56. PubMed ID: 18297114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective Delivery of Doxorubicin to EGFR
    Liu T; Song P; Märcher A; Kjems J; Yang C; Gothelf KV
    Chembiochem; 2019 Apr; 20(8):1014-1018. PubMed ID: 30589193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
    Liao WS; Ho Y; Lin YW; Naveen Raj E; Liu KK; Chen C; Zhou XZ; Lu KP; Chao JI
    Acta Biomater; 2019 Mar; 86():395-405. PubMed ID: 30660004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The ErbB/HER family of protein-tyrosine kinases and cancer.
    Roskoski R
    Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. STAT1 Activation Is Enhanced by Cisplatin and Variably Affected by EGFR Inhibition in HNSCC Cells.
    Schmitt NC; Trivedi S; Ferris RL
    Mol Cancer Ther; 2015 Sep; 14(9):2103-11. PubMed ID: 26141950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel EGFR-specific immunotoxins based on panitumumab and cetuximab show in vitro and ex vivo activity against different tumor entities.
    Niesen J; Stein C; Brehm H; Hehmann-Titt G; Fendel R; Melmer G; Fischer R; Barth S
    J Cancer Res Clin Oncol; 2015 Dec; 141(12):2079-95. PubMed ID: 25899161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.